nemolizumab
galderma
['nemolizumab', 'derm']
late-breaking phase 3 data presented at #aad23 on nemolizumab monotherapy indicates substantial improvement in key primary &amp; secondary endpoints for #prurigonodularis patients. check out the data here: #dermatology #pn #aad2023
Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.